Pharma Firms Alarmed By Australian Plans To Raise GMP Fees
Executive Summary
Medicines Australia says that none of the options for recovering GMP costs set out in its consultation earlier this year are suitable, although views among individual pharmaceutical companies differ.
You may also be interested in...
Australia's Revised GMP Fee To Apply From 1 July
Under Australia's new fee model for good manufacturing practice inspections, domestic manufacturers will no longer be able to accrue unbillable “free inspection hours.” Any residual free hours will expire on July 1, 2020.
Australia Plans Changes To GMP Fee Structure To Help Cover Costs
Australia is planning changes to the way it charges pharmaceutical manufacturers for activities related to good manufacturing practice, such as inspections, because the current arrangements do not allow it to recover its costs.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.